#USA #Miami #PreciseBreast #Oncotype DX #COTA

Transforming Breast Cancer Diagnostics with AI

Recent study outcomes from COTA Inc., PreciseDx, and Baptist Health South Florida assert that the innovative AI-enabled PreciseBreast™ test is equivalent to the Oncotype DX test when predicting breast cancer recurrence. This finding underscores a significant advancement in oncology diagnostics, particularly vital as breast cancer becomes a leading concern in women's health.

The Critical Need for Enhanced Breast Cancer Testing

Breast cancer is a prevalent malignancy, representing approximately 32% of all new cancer cases diagnosed in women in the United States. The sobering statistic reveals that one in eight women will face a breast cancer diagnosis in her lifetime. Given this epidemic, effective diagnostic tools that utilize real-world data (RWD) and artificial intelligence (AI) are essential for improving early detection and speeding up treatment processes.

The new collaboration between COTA, PreciseDx, and Baptist Health South Florida aimed to validate the effectiveness of the PreciseBreast™ test, which evaluates the risk of Invasive Breast Cancer (IBC) recurrence. This innovative test combines demographic and pathology information—including age, tumor dimensions, and lymph node involvement—melding this data with biological markers to enhance predictive accuracy.

Study Details and Key Findings

Presented at the prestigious San Antonio Breast Cancer Symposium (SABCS), the study involved a diverse cohort of 425 patients from the Miami Cancer Institute alongside Baptist Health South Florida, utilizing COTA's curated RWD. Remarkably, the results revealed that PreciseBreast is statistically equivalent to Oncotype DX across six-year outcome data points.

What the study specifically highlighted was:

• - Negative Predictive Value (NPV) of 93% for identifying recurrence risk.
• - Risk Classification Comparison: 79% of patients were considered low risk by PreciseBreast compared to 81% as low/intermediate risk by Oncotype DX, with both showing similar chemotherapy avoidance rates.
• - Event Confirmation: Among patients who had recurrences, PreciseBreast successfully classified 38% as high risk versus 35% for Oncotype DX.

The Significance of AI in Oncology

Dr. C.K. Wang, COTA's chief medical officer, articulates the potential impact of AI in this domain by stating, “These results illustrate how AI-powered tools can significantly enhance cancer diagnostics and treatment precision.” The emphasis on research-grade RWD for AI training is a cornerstone in fostering trust and ensuring responsible integration of these technologies into everyday medical practices.

In spite of improvements in gene-expression testing, Oncotype DX remains financially burdensome and often leads to prolonged waiting periods for results. In stark contrast, PreciseBreast reduces costs by 80% with a reporting timeframe of just 48 hours, thus alleviating patient anxiety during critical periods and facilitating timely treatment decisions.

Future Directions and Implications

These substantial findings pave the way for improved practices in oncology. As PreciseBreast continues to undergo extensive validation, its implementation may transform standard cancer care protocols. With the capabilities to provide healthcare professionals and patients with timely, detailed insights into cancer recurrence risks, PreciseBreast stands to support informed choices in treatment pathways.

In summary, as health professionals strive for comprehensive care planning, PreciseBreast's API-powered approach highlights a transformative step forward in breast cancer management. It emphasizes the necessity for an integrated approach to diagnostics that combines both technological innovation and patient-centered care—ultimately crafting a brighter future in oncology diagnostics.